Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.33 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | GLB1 | P16278 | 2/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 2/20 | 0.30 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12536225 | 1.00 | GBA1 (0.33) | GBA1MAN1B1GAAGLB1PYGL | |
| SCHEMBL12536233 | 0.82 | GBA1 (0.34) | GBA1MAN1B1GAAGLB1PYGL | |
| SCHEMBL28316228 | 0.80 | CA1 (0.52) | GBA1MAN1B1GAAGLB1PYGL | |
| SCHEMBL13906097 | 0.80 | CA1 (0.52) | GBA1MAN1B1GAAGLB1PYGL | |
| SCHEMBL12561505 | 0.80 | CA1 (0.52) | GBA1MAN1B1GAAGLB1PYGL | |
| SCHEMBL13483770 | 0.78 | KCNH2 (0.31) | KCNH2HRH4HRH3HRH2 | |
| SCHEMBL2897071 | 0.78 | GBA1 (0.43) | GBA1MAN1B1GAAGLB1PYGL | |
| SCHEMBL12561507 | 0.77 | GLB1 (0.40) | GBA1GLB1GBA2CA1CA2 | |
| SCHEMBL12561509 | 0.77 | GLB1 (0.40) | GBA1GLB1GBA2CA1CA2 | |
| SCHEMBL12536215 | 0.77 | KCNH2 (0.31) | KCNH2HRH4HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | GBA1 3186/4885MAN1B1 3323/4885GAA 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.